Abigail Norris Turner1, Patricia Carr Reese2, Karen S Fields3, Julie Anderson3, Melissa Ervin3, John A Davis2, Raina N Fichorova4, Mysheika Williams Roberts3, Mark A Klebanoff5, Rebecca D Jackson6. 1. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, the Ohio State University, Columbus, OH. Electronic address: ant@osumc.edu. 2. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, the Ohio State University, Columbus, OH. 3. Sexual Health Clinic, Columbus Public Health, Columbus, OH. 4. Department of Obstetrics, Gynecology, and Reproductive Biology, Laboratory of Genital Tract Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 5. Departments of Pediatrics and Obstetrics and Gynecology, College of Medicine, the Ohio State University, Columbus, OH; Research Institute at Nationwide Children's Hospital, Columbus, OH. 6. Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, College of Medicine, the Ohio State University, Columbus, OH.
Abstract
OBJECTIVE:Low serum vitamin D levels have been associated with increased prevalence of the reproductive tract condition bacterial vaginosis (BV). The objective of this trial was to evaluate the effect of high-dose vitamin D supplementation on BV recurrence. STUDY DESIGN: This randomized, placebo-controlled, double-blinded trial enrolled 118 women with symptomatic BV from an urban sexually transmitted disease clinic (clinicaltrials.gov registration NCT01450462). All participants received 500 mg of oral metronidazole twice daily for 7 days. Intervention participants (n = 59) also received 9 doses of 50,000 IU of cholecalciferol (vitamin D3) over 24 weeks; control women (n = 59) received matching placebo. Recurrent BV was assessed via Nugent scoring after 4, 12, and 24 weeks. We assessed the effect of the intervention using an intention-to-treat approach, fitting Cox proportional hazards models to evaluate recurrent BV over the follow-up period. RESULTS:Most participants (74%) were black, with a median age of 26 years. Median presupplementation serum 25-hydroxyvitamin D [25(OH)D] was similar across randomization arms: 16.6 ng/mL in the vitamin D arm and 15.8 ng/mL in the control arm. At trial completion, median 25(OH)D among women receiving vitamin D was 30.5 ng/mL, vs 17.8 ng/mL in control women; 16% of women receiving vitamin D and 57% receiving placebo remained vitamin D deficient (<20 ng/mL). BV prevalence among women randomized to vitamin D was very similar to those randomized to placebo at the 4- and 12-week visits, but by the 24-week visit, BV prevalence was 65% among women in the vitamin D arm and 48% among control women. BV recurrence was not reduced by vitamin D supplementation (intention-to-treat hazard ratio, 1.11; 95% confidence interval, 0.68-1.81). Among women experiencing recurrent BV, median time to recurrence was 13.7 weeks in the vitamin D arm and 14.3 weeks in the control arm. CONCLUSION: Women receiving vitamin D experienced significant increases in serum 25(OH)D, but this increase was not associated with decreased BV recurrence in this high-risk sexually transmitted disease clinic population.
RCT Entities:
OBJECTIVE: Low serum vitamin D levels have been associated with increased prevalence of the reproductive tract condition bacterial vaginosis (BV). The objective of this trial was to evaluate the effect of high-dose vitamin D supplementation on BV recurrence. STUDY DESIGN: This randomized, placebo-controlled, double-blinded trial enrolled 118 women with symptomatic BV from an urban sexually transmitted disease clinic (clinicaltrials.gov registration NCT01450462). All participants received 500 mg of oral metronidazole twice daily for 7 days. Intervention participants (n = 59) also received 9 doses of 50,000 IU of cholecalciferol (vitamin D3) over 24 weeks; control women (n = 59) received matching placebo. Recurrent BV was assessed via Nugent scoring after 4, 12, and 24 weeks. We assessed the effect of the intervention using an intention-to-treat approach, fittingCox proportional hazards models to evaluate recurrent BV over the follow-up period. RESULTS: Most participants (74%) were black, with a median age of 26 years. Median presupplementation serum 25-hydroxyvitamin D [25(OH)D] was similar across randomization arms: 16.6 ng/mL in the vitamin D arm and 15.8 ng/mL in the control arm. At trial completion, median 25(OH)D among women receiving vitamin D was 30.5 ng/mL, vs 17.8 ng/mL in control women; 16% of women receiving vitamin D and 57% receiving placebo remained vitamin D deficient (<20 ng/mL). BV prevalence among women randomized to vitamin D was very similar to those randomized to placebo at the 4- and 12-week visits, but by the 24-week visit, BV prevalence was 65% among women in the vitamin D arm and 48% among control women. BV recurrence was not reduced by vitamin D supplementation (intention-to-treat hazard ratio, 1.11; 95% confidence interval, 0.68-1.81). Among women experiencing recurrent BV, median time to recurrence was 13.7 weeks in the vitamin D arm and 14.3 weeks in the control arm. CONCLUSION:Women receiving vitamin D experienced significant increases in serum 25(OH)D, but this increase was not associated with decreased BV recurrence in this high-risk sexually transmitted disease clinic population.
Authors: David Moher; Sally Hopewell; Kenneth F Schulz; Victor Montori; Peter C Gøtzsche; P J Devereaux; Diana Elbourne; Matthias Egger; Douglas G Altman Journal: BMJ Date: 2010-03-23
Authors: Audrey L French; Oluwatoyin M Adeyemi; Denis M Agniel; Charlesnika T Evans; Michael T Yin; Kathryn Anastos; Mardge H Cohen Journal: J Womens Health (Larchmt) Date: 2011-08-29 Impact factor: 2.681
Authors: Carol L Wagner; Rebecca B McNeil; Donna D Johnson; Thomas C Hulsey; Myla Ebeling; Christopher Robinson; Stuart A Hamilton; Bruce W Hollis Journal: J Steroid Biochem Mol Biol Date: 2013-01-10 Impact factor: 4.292
Authors: Abigail Norris Turner; Patricia Carr Reese; Margaret Christine Snead; Karen Fields; Melissa Ervin; Athena P Kourtis; Mark A Klebanoff; Maria F Gallo Journal: Sex Transm Dis Date: 2016-03 Impact factor: 2.830
Authors: Abigail N Turner; Patricia Carr Reese; Pai Lien Chen; Cynthia Kwok; Rebecca D Jackson; Mark A Klebanoff; Raina N Fichorova; Tsungai Chipato; Charles S Morrison Journal: Am J Obstet Gynecol Date: 2016-03-02 Impact factor: 8.661
Authors: Kimberly K Jefferson; Hardik I Parikh; Erin M Garcia; David J Edwards; Myrna G Serrano; Martin Hewison; Judith R Shary; Anna M Powell; Bruce W Hollis; Jennifer M Fettweis; Jerome F Strauss Iii; Gregory A Buck; Carol L Wagner Journal: J Perinatol Date: 2019-03-11 Impact factor: 2.521
Authors: Anne L Dunlop; Sheila L Jordan; Erin P Ferranti; Cherie C Hill; Shiven Patel; Li Hao; Elizabeth J Corwin; Vin Tangpricha Journal: Infect Dis Obstet Gynecol Date: 2019-01-01
Authors: Daniela Machado; Joana Castro; Ana Palmeira-de-Oliveira; José Martinez-de-Oliveira; Nuno Cerca Journal: Front Microbiol Date: 2016-01-20 Impact factor: 5.640